1-4 of 4
Mark DeMario
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

Didier Meulendijks, Ulrik N. Lassen, Lillian L. Siu, Alwin D.R. Huitema, Vaios Karanikas, Morten Mau-Sorensen, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Karen Wang, Mark DeMario, Glenwood D. Goss, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 858–867.
https://doi.org/10.1158/1078-0432.CCR-15-1506
Published: 14 February 2016
View article titled, Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Open the PDF for Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors in another window
Journal Articles

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

Ulrik N. Lassen, Didier Meulendijks, Lilian L. Siu, Vaios Karanikas, Morten Mau-Sorensen, Jan H.M. Schellens, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Ka Wang, Mark DeMario, Glenwood D. Goss
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 258–266.
https://doi.org/10.1158/1078-0432.CCR-14-1334
Published: 14 January 2015
View article titled, A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
Open the PDF for A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers in another window
Includes: Supplementary data
Journal Articles

RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Xuefeng Yin, Leopoldo Luistro, Hua Zhong, Melissa Smith, Tom Nevins, Kathleen Schostack, Holly Hilton, Tai-An Lin, Theresa Truitt, Denise Biondi, Xiaoqian Wang, Kathryn Packman, Jim Rosinski, Windy Berkofsky-Fessler, Jian-Ping Tang, Saumya Pant, David Geho, Suzana Vega-Harring, Mark DeMario, Hy Levitsky, Mary Simcox
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (20): 5686–5698.
https://doi.org/10.1158/1078-0432.CCR-13-0405
Published: 14 October 2013
View article titled, RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
Open the PDF for RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

Ramon Salazar, Donald Bissett, Chris Twelves, Lars Breimer, Mark DeMario, Sophia Campbell, Jay Zhi, Steve Ritland, Jim Cassidy
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4374–4382.
https://doi.org/10.1158/1078-0432.CCR-04-0135
Published: 06 July 2004
View article titled, A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors
Open the PDF for A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors in another window